دورية أكاديمية
The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
| العنوان: | The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
|---|---|
| المؤلفون: | Shi-Yu Ye, Jia-Yi Li, Teng-Hui Li, Yong-Xi Song, Jing-Xu Sun, Xiao-Wan Chen, Jun-Hua Zhao, Yuan Li, Zhong-Hua Wu, Peng Gao, Xuan-Zhang Huang |
| المصدر: | Current Oncology, Vol 29, Iss 9, Pp 6137-6153 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | cancer therapy, meta-analysis, celecoxib, survival, local control, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy. Randomized controlled trials (RCTs) that evaluated the efficacy and safety of celecoxib-combined cancer therapy were systematically searched in PubMed and Embase databases. The endpoints were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), objective response rate (ORR), disease control rate (DCR), pathological complete response (pCR), and adverse events (AEs). The results of 30 RCTs containing 9655 patients showed limited benefits in celecoxib-combined cancer therapy. However, celecoxib-combined palliative therapy prolonged PFS in epidermal growth factor receptor (EGFR) wild-type patients (HR = 0.57, 95%CI = 0.35–0.94). Moreover, despite a slight increase in thrombocytopenia (RR = 1.35, 95%CI = 1.08–1.69), there was no increase in other toxicities. Celecoxib combined with adjuvant therapy indicated a better OS (HR = 0.850, 95%CI = 0.725–0.996). Furthermore, celecoxib plus neoadjuvant therapy improved the ORR in standard cancer therapy, especially neoadjuvant therapy (overall: RR = 1.13, 95%CI = 1.03–1.23; neoadjuvant therapy: RR = 1.25, 95%CI = 1.09–1.44), but not pCR. Our study indicated that adding celecoxib to palliative therapy prolongs the PFS of EGFR wild-type patients, with good safety profiles. Celecoxib combined with adjuvant therapy prolongs OS, and celecoxib plus neoadjuvant therapy improves the ORR. Thus, celecoxib-combined cancer therapy may be a promising therapy strategy. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 29090482 1718-7729 1198-0052 |
| Relation: | https://www.mdpi.com/1718-7729/29/9/482; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729 |
| DOI: | 10.3390/curroncol29090482 |
| URL الوصول: | https://doaj.org/article/6a2ddcaa536449f0b67b806f39dfa514 |
| رقم الأكسشن: | edsdoj.6a2ddcaa536449f0b67b806f39dfa514 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 29090482 17187729 11980052 |
|---|---|
| DOI: | 10.3390/curroncol29090482 |